2nd Quarter - Report

CHAMBER HILL STRATEGIES for AMAG PHARMACEUTICALS (FORMERLY KNOWN AS LUMARA PHARMACEUTICAL)

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
$40,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report (this page) Jul 2, 2014 $40,000 Replaced
2nd Quarter - Amendment Jul 23, 2014 $60,000 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Implementation issues related to P.L. 113-54, the Drug Quality and Security Act

LobbyistCovered position, as disclosed
JENNIFER BELL Legislative Assistant, Rep. John Thune (R-SD)
ADAM ETZION —
JENNIFER HIGGINS —
MICHAELA SIMS Legislative Counsel, Sen. Bob Kerrey

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.